Login to Your Account

FDA Questions Replagal Data; TKT's Stock Falls 60 Percent

By Kim Coghill

Friday, October 4, 2002
The race between Transkaryotic Therapies Inc. and Genzyme General to win regulatory approval plus orphan drug designation for their respective Fabry's disease biologics evolved late Wednesday when Transkaryotic said the FDA expressed concerns about some of its data. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription